Purpose. Neuroblastoma is a rare childhood cancer whose high risk, metastatic form has a dismal outcome in spite of aggressive therapeutic interventions. The toxicity of drug treatments is a major problem in this paediatric setting. In this study, we investigated whether Polyphenon E, a clinical grade mixture of green tea catechins under evaluation in multiple clinical cancer trials run by the NCI, has anticancer activity in mouse models of neuroblastoma. 
Conclusions. These findings suggest that the neuroblastoma-promoting activity of MDSCs can be manipulated pharmacologically in vivo and that green tea catechins operate at least in part through this mechanism.
Translational relevance. In spite of its low frequency, neuroblastoma is a malignancy that accounts for 15% of all oncological childhood deaths. Current treatments include heavy chemotherapy, radiation and surgery, which often cause long lasting adverse effects. Polyphenol E is an orally available, clinical grade catechin formulation, which in adult clinical trials has shown no toxicity or adverse effects. In this study, we show that the catechin mixture significantly inhibits tumourigenesis in mouse models of neuroblastoma by inactivating cancer-induced suppressive myeloid cells. Polyphenol E caused maturation of myeloid cells, inhibition of their immunosuppressive effects and reactivation of patient's intratumoural T cells. These results suggest that oral administration of Polyphenon E could be particularly useful to enhance the efficacy of cancer immunotherapy. Specifically, we predict that Polyphenon E should augment the antitumour immune response in neuroblastoma patients injected with therapeutic antibodies targeting the GD2 molecule. The observation that Polyphenol E significantly reduces spontaneous tumourigenesis in TH-MYCN mice indicates that the formulation could also be used to prevent recurrence after cancer remission induced by standard therapies.
Introduction
Green tea has been used for thousands of years in traditional Chinese medicine to treat human disease. Epidemiologic data demonstrates that Asian populations that consume significant quantities of green tea show a reduced incidence of cancer (1) . Green tea catechins are natural polyphenolic formulations endowed with anti-oxidant and anti-cancer activity. In recent years a number of reports have shown that green tea catechins inhibit tumour proliferation and induce tumour cell apoptosis in vivo and in vitro (2) . A small placebo-controlled randomized study in subjects with high-grade prostate intraepithelial neoplasia showed that there was a significant reduction in the development of prostate cancer in patients taking 600 mg catechins per day (3) . Therapeutic concentrations may be achieved by accumulation in target tissues, but are associated with minimal toxicity during prolonged treatments (1, 3, 4) . The mechanisms of action have not been clarified, although it has been proposed that catechins modulate key molecular drivers of cell proliferation and survival, including cyclin D1 (5) . Polyphenon E is a green tea catechin formulation, which has been shown to prevent tumourigenesis in cancer clinical trials (3, (5) (6) (7) . To further explore efficacy and mechanism, Polyphenon E was supplemented in the drinking water (0.3% w/v) of neuroblastoma prone TH-MYCN transgenic mice (8) . Unexpectedly, we found that the anti-cancer effects of Polyphenon E could be mediated by the immune system.
Materials and Methods
Reagents. Polyphenon E was kindly provided by Andrew Munro, Polyphenonpharma NY, USA. Polyphenon E contains 53% EGCG, 9% epicatechin, 11% (−)-epigallocatechin, 5% epicatechin-3-gallate, and 5% (−)-gallocatechin epicatechin, 0.55 μg/mL (−)-epigallocatechin, and 0.25 μg/mL (−)-gallocatechin gallate. The same batch of the formulation was used throughout this study. The Polyphenol E powder was dissolved into 100 ml of drinking water freshly prepared every other day. supplemented with 1% penicillin/streptomycin and full cytokine cocktail (100 ng/ml mSCF, 100 ng/ml mFlt3L, 100 ng/ml hIL-11, 20 ng/ml mIL-3). To obtain bone marrow-derived MDSCs, 2.5x10 Statistical analysis. Kaplan-Meier surviving curves and log-rank test were used to compare the survival of TH-MYCN mice treated with Polyphenon E.
All other results are presented as mean values ± SE and the significance calculated using Student's T test.
Results

The anti-cancer activity of Polyphenon E in mouse models of neuroblastoma requires the immune system and is associated with impaired infiltration of myeloid cells
There 
Promotion of neuroblastoma growth in vivo by tumour-induced myeloid cells is antagonized by Polyphenon E, which requires the activity of CD8 T cells
To assess the role of myeloid cells in tumour growth in this setting, we co- 
Polyphenon E antagonizes the immunosuppressive activity of myeloid cells
To assess whether catechins not only affected the differentiation but also the immunosuppressive activity of myeloid cells, we separated vehicle or Polyphenon E treated monocytic MDSCs (CD11b+/Ly6G-ve/Ly6Chigh) by flow cytometric sorting, and mixed them with CD3+ splenic T lymphocytes.
Secretion of interferon gamma (IFN-) was determined after stimulation with
anti-CD3 and anti-CD28 antibodies. As expected, monocytic MDSCs showed a decline in absolute lymphocytic counts and/or lymphoadenopathy in the majority of patients (6) . Importantly, the formulation was non-toxic and very well tolerated even at very high dosages (6) . More recently, a placebo controlled study in prostate cancer patients before prostatectomy showed favorable changes in serum prostate specific antigen and a decrease in
Gleason score between biopsy and surgical specimens in the Polyphenon E arm, although the differences were not statistically significant (26).
In this pre-clinical study using mouse models of neuroblastoma, we have shown that Polyphenon E has a significant anti-cancer activity in both prophylactic (MYCN model) and therapeutic (AJ model) settings, suggesting that the formulation could be potentially used in neuroblastoma children as a chemopreventive agent during cancer remission or during therapy in combination with chemotherapeutic drugs. Importantly, our study demonstrates that the anticancer effect is only significant in the context of a functioning immune system and that it occurs via inhibition of MDSCs.
Another important observation in our study is the drastic increase of immunosuppressive cells bearing myeloid markers in a small cohort of children with neuroblastoma (supplementary table 1 and figure 6 ). While this finding needs to be confirmed in a larger cohort of patients, to our knowledge this is the first documentation of MDSC-like cells in neuroblastoma patients.
The mechanism by which Polyphenon E disables MDSCs is probably the induction of terminal differentiation ( figure 4) . We show that G-CSF is the key cytokine required to mediate the differentiation activity of Polyphenon E and that signalling from the 67kDa laminin receptor is implicated in MDSCs maturation. This is a notable finding since the pathways activated downstream of this receptor, when identified, could be exploited for therapeutic purposes.
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